Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of CRC tumor organoids engineered with key driver mutations

ABSTRACT: We profiled CRC organoids engineered with different combinations of driver mutations. All organoids were derived from one mouse and then mutations were sequentially introduced by CRISPR Cas9

ORGANISM(S): Mus musculus

PROVIDER: GSE207668 | GEO | 2022/09/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic characterization of FLC-mutant engineered human hepatocyte organoids

Project description:We engineered human hepatocyte organoids to study the effect of different fibrolamellar carcinoma mutations. To study the effects and differences between the different mutations, we performed bulk RNA-sequencing to understand the transcriptomic changes.

2023-03-15 | GSE215785 | GEO

Exome sequencing of CRC organoids

Project description:Propagation of primary CRCs into organoids

| PRJEB7932 | ENA

Illumina Infinium HumanMethylation EPIC beadchip profiling of BRAF-V600E_knock-in and BRAF-wildtype human colon organoids

Project description:We aimed to investigate genome wide DNA methylation changes in human colon organoids in which the BRAF-V600E mutation was introduced by means of CRISPR genome editing and in BRAF-wildtype human colon cancer organoids. DNA methylation analysis was performed using the Infinium Methylation EPIC beadchip at the Pathology department of the UMC Utrecht (The Netherlands).

2023-12-20 | E-MTAB-13290 | biostudies-arrayexpress

Probing the Tumour Suppressor Function of BAP1 in CRISPR-engineered Human Liver Organoids

Project description:The deubiquitinating enzyme BAP1 is a tumour suppressor, amongst others involved in cholangiocarcinoma. BAP1 has many proposed molecular targets, while its Drosophila homolog is known to deubiquitinate Histone H2AK119. Here, we mutate BAP1 by CRISPR/Cas9 in normal human liver organoids. We find that BAP1 controls the expression of junctional/cytoskeleton components by regulating chromatin accessibility. Consequently, we observe loss of multiple epithelial characteristics, while motility increases. Importantly, restoring the catalytic activity of BAP1 in the nucleus rescues these cellular and molecular changes. We engineer human liver organoids to combine four common cholangiocarcinoma mutations (TP53, PTEN, SMAD4, NF1). In this genetic background, BAP1 loss results in acquisition of malignant features upon xenotransplantation. Thus, control of epithelial identity through the regulation of chromatin accessibility appears a key aspect of BAP1’s tumour suppressor function. Organoid technology combined with CRISPR/Cas9 provides an experimental platform for mechanistic studies of cancer gene function in a human context.

2019-05-22 | PXD013353 | Pride

Lipid Profiling of Mouse Intestinal Organoids for studying APC Mutations

Project description:Inactivating mutations including both germline and somatic mutations in the adenomatous polyposis coli (APC) gene drives most familial and sporadic colorectal cancers. Understanding the metabolic implications of this mutation will aid to establish its wider impact on cellular behaviour and potentially inform clinical decisions. However, to date, alterations in lipid metabolism induced by APC mutations remain unclear. Intestinal organoids have gained widespread popularity in studying colorectal cancer and chemotherapies, because their three-dimensional structure more accurately mimics an in vivo environment. Here, we aimed to investigate intra-cellular lipid disturbances induced by APC gene mutations in intestinal organoids using a reversed-phase ultra-high-performance liquid chromatography mass spectrometry (RP-UHPLC-MS)-based lipid profiling method. Lipids of the organoids grown from either wildtype (WT) or mice with Apc mutations (Lgr5–EGFP-IRES-CreERT2 Apcfl/fl) were extracted and analysed using RP-UHPLC-MS. Concentrations of phospholipids (e.g. PC(16:0/16:0), PC(18:1/20:0), PC(38:0), PC(18:1/22:1)), ceramides (e.g. Cer(d18:0/22:0), Cer(d42:0), Cer(d18:1/24:1)) and hexosylceramide (e.g. HexCer(d18:1/16:0), HexCer(d18:1/22:0)) were higher in Apcfl/fl organoids, whereas levels of sphingomyelins (e.g. SM(d18:1/14:0), SM(d18:1/16:0) ) were lower compared to WT. These observations indicate that cellular metabolism of sphingomyelin was upregulated, resulting in the cellular accumulation of ceramides and production of HexCer due to the absence of Apcfl/fl in the organoids. Our observations demonstrated lipid profiling of organoids and provided an enhanced insight into the effects of the APC mutations on lipid metabolism, making for a valuable addition to screening options of the organoid lipidome.

2021-02-17 | ST001707 | MetabolomicsWorkbench

Transcriptome profiling (RNA-seq) of chemotherapy treated CRC organoids

Project description:The main goal of this study was to analyze transcriptional differences between AKP CRC organoids treated or not with chemotherapy (FOLFIRI) by RNA-seq.

2022-09-16 | GSE207974 | GEO

Single-cell RNA-seq of engineered healthy human kidney organoids

Project description:Single-cell RNA-seq of engineered healthy human kidney organoids. These data are part of a larger investigation (data not provided here) showing that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids which can be inhibited by human recombinant soluble ACE2 (hrsACE2), demonstrating that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.

2020-04-05 | GSE147863 | GEO

Expression data from CRC patient-derived organoids

Project description:Colorectal cancer (CRC) is a commonly occurring cancer worldwide. Metastasis and recurrence are the major causes of cancer-related death. CRC progression is a multistep process, and extensive efforts have been made to identify the genomic and transcriptomic alterations that occur during this process. However, whether primary tumors and metastatic lesions possess distinct biological features remains unclear. We established 74 patient-derived organoids (PDOs) from primary tumors and patient-matched metastatic and recurrent lesions.

2021-04-01 | GSE128213 | GEO

Expression data from CRC patient-derived organoids

Project description:Expression data from CRC patient-derived organoids

| PRJNA526815 | ENA

Genetically engineered endothelial niche induces vascularization in human kidney organoids

Project description:Here we developed a method to incorporate a genetically engineered endothelial niche into an established protocol for generating human kidney organoids.

2023-05-22 | GSE232767 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data